Project Grant K99AI199056
- Federal Project Grant Award Summary Virginia Commonwealth University received a $426,939 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period July 1, 2025, through June 30, 2027. The award supports research investigating the modulation of human cytomegalovirus (CMV) replication by the viral temperance factor RL13, a virion-associated envelope glycoprotein. The research aims...
- Federal Grant Award Summary Virginia Commonwealth University received a $404,273 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 23, 2025, with a completion date of June 30, 2027. The research project investigates the pathogenic effects of Sneathia vaginalis on amniotic membrane tissues and their role in preterm birth and preterm premature rupture of membranes. As a...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Virginia a Project Grant totaling $795,990 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 23, 2026, with a completion date of March 31, 2031. This award supports a comprehensive research initiative to identify and target antimicrobial resistance (AMR) gene superspreaders within hospital ecosystems. The project addresses the critical...
- Federal Project Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $422,355 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 23, 2025, with completion targeted for June 30, 2027. The grant funds mechanistic and structural studies examining the signaling histidine kinase GacS from Pseudomonas aeruginosa, a nosocomial...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Virginia a $1,201,716 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 6, 2025, for research titled "Chemical Grammar of Accumulation in Drug Resistant Acinetobacter baumannii with Subcellular Resolution." The project, with performance in Charlottesville, Virginia, and completion scheduled for July 31, 2030, will develop...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Virginia a Project Grant of $450,766 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 8, 2025, with completion targeted for July 31, 2027. This research initiative aims to characterize how Chlamydia trachomatis, the leading cause of bacterial sexually transmitted infections, remodels inter-organelle communication within host cells to create a...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Virginia a $3.05 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 12, 2025, with an ultimate completion date of August 31, 2029. The research project investigates paired receptor signaling in natural killer (NK) cells to understand how NK cell receptor polymorphism affects antiviral immunity and viral control. The...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Virginia $444,125 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 10, 2026, with a completion date of January 31, 2028. This Project Grant funds a comprehensive immunological analysis of human rhinovirus (RV) infections, with research to be conducted in Charlottesville, Virginia. The project delivers advanced scientific investigation into...
- Federal Grant Award Summary The University of Virginia received a $146,170 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 9, 2025 through April 30, 2030. This award supports the development of a global infectious diseases research framework designed to advance interdisciplinary collaboration among junior faculty and researchers engaged in global health...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Virginia a $773,388 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) beginning April 1, 2026, with a completion date of March 31, 2031. This five-year research initiative, titled "Decoding Cellular Networks Governing Respiratory Mucosal IgA Immunity," will investigate the cellular and molecular mechanisms that drive robust...
Virginia Commonwealth University received a $138,861 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on May 7, 2026, with a completion date of April 30, 2028. The research investigates how Orientia tsutsugamushi, the bacterium responsible for scrub typhus, manipulates host cell pathways to evade immune responses and enable intracellular replication in endothelial cells. The project examines the interplay between circadian rhythm and hypoxic response mechanisms that the pathogen exploits to suppress innate immune defenses, with particular focus on the bacterial effector protein ANK13 and its role in modulating host gene expression and preventing DNA damage-induced apoptosis. This research addresses a critical gap in understanding host-pathogen interactions in scrub typhus, a globally emerging infection with high fatality rates. The findings are intended to advance scientific knowledge of bacterial survival mechanisms and inform the development of therapeutic interventions targeting the circadian-hypoxic response axis as a novel approach to combating this intractable obligate intracellular pathogen. The project leverages VCU's established capacity in biomedical research and contributes to the broader NIAID mission of supporting investigator-initiated research to improve public health outcomes in infectious disease.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $138.9k | 5/11/26 |